Li Xue-Yang, Hu Yi, Li Nian-Shuang, Wan Jian-Hua, Zhu Yin, Lu Nong-Hua
Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi Province, China.
Gastroenterol Res Pract. 2019 Mar 10;2019:5625026. doi: 10.1155/2019/5625026. eCollection 2019.
The receptor of activated protein kinase C 1 (RACK1) promotes the progression and invasion of several cancers. However, the role of RACK1 in the pathogenesis of colorectal cancer (CRC) has not been clearly defined. Herein, we aimed to investigate the biological role of RACK1 in CRC.
The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) dataset were searched, and the expression of RACK1 in CRC tissues and adjacent normal tissues was evaluated. Immunohistochemical staining was performed to detect the expression of RACK1 in human CRC, adenoma, and normal tissues. Western blotting was used to detect the expression of RACK1 in human CRC cell lines. Functional assays, such as BrdU, colony formation, and wound healing and transwell invasion assays, were used to explore the biological role of RACK1 in CRC.
RACK1 was upregulated in CRC tissues compared with its expression in adjacent normal tissues in TCGA and the GEO dataset ( < 0.05). Moreover, RACK1 was significantly overexpressed in CRC and adenoma tissues compared with its expression in normal tissues ( < 0.05). Loss-of-function experiments showed that RACK1 promoted cell proliferation, migration, and invasion .
Our data indicated that RACK1, as an oncogene, markedly promoted the progression of CRC, which suggested that RACK1 is a potential therapeutic target for CRC management.
活化蛋白激酶C 1受体(RACK1)促进多种癌症的进展和侵袭。然而,RACK1在结直肠癌(CRC)发病机制中的作用尚未明确界定。在此,我们旨在研究RACK1在CRC中的生物学作用。
检索癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)数据集,评估RACK1在CRC组织和相邻正常组织中的表达。进行免疫组织化学染色以检测RACK1在人CRC、腺瘤和正常组织中的表达。使用蛋白质免疫印迹法检测RACK1在人CRC细胞系中的表达。采用功能试验,如BrdU、集落形成、伤口愈合和Transwell侵袭试验,以探究RACK1在CRC中的生物学作用。
在TCGA和GEO数据集中,与相邻正常组织中的表达相比,RACK1在CRC组织中上调(<0.05)。此外,与正常组织中的表达相比,RACK1在CRC和腺瘤组织中显著过表达(<0.05)。功能缺失实验表明,RACK1促进细胞增殖、迁移和侵袭。
我们的数据表明,RACK1作为一种癌基因,显著促进了CRC的进展,这表明RACK1是CRC治疗管理的潜在靶点。